Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Inspire and Antidote Launch End-to-End Clinical Trial Recruitment Solution to Accelerate Medical Research

Posted on: 04 Jan 18

ARLINGTON, Va. and NEW YORK, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Inspire, the leading healthcare social network, and Antidote, a digital health company that connects patients with research, announced a strategic collaboration today that will provide an unparalleled end-to-end patient recruitment model to pharmaceutical companies and CROs. The solution, Inspire Recruit, combines Inspire’s trusted community of over 1.2 million members and Antidote’s advanced patient engagement services to speed up enrollment timelines and accelerate medical research. For trial sponsors, this partnership provides:

  • Unique access to engaged and pre-qualified patient populations across 3,600 medical conditions
  • Highly efficient prescreening technology
  • Effective referral management, such as concierge services to help patients navigate the journey to enrollment
  • Pre-trial insights for patient-centric protocol design, feasibility, and recruitment planning

“Deciding to participate in a clinical trial is one of the most important decisions a patient can make. When we searched for a partner to help our patients through the process of enrolling in a clinical trial, Antidote was a natural fit,” said Inspire CEO Brian Loew. “Antidote combines an innovative clinical trial matching engine with an expert referral management team to help members of Inspire’s large patient community find and enroll in the ideal trial. Our goal is to help personalize and improve the enrollment experience for patients, and I am confident that together, we can have a major impact on patient recruitment.”

Inspire has created a vibrant community that connects people with the same diagnosis, solving a tough problem for patients, especially those with a rare disease or specific cancer mutation. Collectively, Inspire has over a million active users a month. Thousands of new patients and caregivers join each week, and over 4,000 members engage in discussion each day. In addition to encouraging safe, permission-based discussion, Inspire supports patients through partnerships with nonprofit advocacy organizations, expert moderation, and resources.

In the United States today, nearly 80% of clinical trials fail to meet their enrollment timelines [1]; just 19% of patients report feeling “very knowledgeable” about clinical research [2].

“We are proud to partner with Inspire to raise clinical trial awareness and bridge interested patients directly to study sites,” said Pablo Graiver, Founder and CEO of Antidote. “Inspire has cultivated an authentic and supportive community, the ideal place for patients to learn about new study options. Together, our organizations will ensure that volunteers have a seamless journey to medical research participation.”

From engagement to enrollment, Antidote employs technology with a human touch. Having completed over 100 recruitment projects, the company provides customized study microsites and prescreeners, patient-to-trial matching technology, phone validation, site coordination, and more. Its signature technology, Antidote Match™, is the first clinical trial matching engine that uses structured eligibility criteria and algorithms to explore a patient’s eligibility for one or many trials. Match has been embedded as a clinical trial search tool in over 200+ health and patient advocacy websites.

“Patients are very interested in clinical trials; they just don’t know how to go about participating,” said Michael Kaplan, President and CEO of Melanoma Research Alliance, the largest private funder of melanoma research, and partner to both Antidote and Inspire. “To accelerate powerful research and advance cures, we need to foster collaboration and engagement across all stakeholders—including patients."

For more information, please visit or

About Antidote
Antidote is a digital health company on a mission to accelerate the breakthroughs of new treatments by bridging the gap between medical research and the people who need it. In a world where 80% of medical trials are delayed or closed due to lack of participants, Antidote use cutting-edge technology to match the right patients with the right trials, helping medical researchers make faster progress, and offering new treatment options to patients. Antidote Match, the company’s unique trial matching tool, currently powers clinical trial search for more than 210 patient communities and health portals—bringing clinical trial awareness, matching, and access to more than 15 million patients a month. Antidote was launched as TrialReach and is based in the US and UK. For more information, please visit

About Inspire
Inspire ( is the leading healthcare social network, with a mission to accelerate medical progress through a world of connected patients. Partnering with over 100 nonprofit patient advocacy organizations, Inspire creates and manages support communities for more than one million patients and caregivers, representing more than 3,600 health conditions. The company helps pharmaceutical companies integrate patient-centricity into the pharmaceutical product lifecycle, from clinical trial design and recruitment to post-marketing brand/unbranded activities.

Media Contact
John Novack
Director of Communications, Inspire 
(800) 945-0381

Lisa Conroy
Director of Communications, Antidote 
(215) 872-2917

[1] Chris Trizna, in Re-Engineering Clinical Trials, 2015
[2] CISCRP, 2015


Last updated on: 04/01/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.